tbuckley/cabot-search huggingface dataset:
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma
Authors: Aude Fléchon, Rafael Morales-Barrera, Thomas Powles, Ajjai Alva, Mustafa Özgüroğlu, Tibor Csöszi, Yohann Loriot, Alejo Rodriguez-Vida, Lajos Géczi, Susanna Y. Cheng, Yves Fradet, Stéphane Oudard, Christof Vulsteke, Seyda Gunduz, Ronac Mamtani, Evan Y. Yu, Alvaro Montesa Pino, Urbano Anido, Mehmet A.N. Sendur, Gwenaelle Gravis, János Révész, Vladimir Kostorov, Olivier Huillard, Junshui Ma, Mohini Rajasagi, Amir Vajdi, Jared Lunceford, Razvan Cristescu, Kentaro Imai, Blanca Homet Moreno, Nobuaki Matsubara
Journal: Clinical Cancer Research (2024)

Abstract Purpose: The three-arm, phase III KEYNOTE-361 study did not meet its dual primary endpoints of progression-free survival (PFS) or overall survival (OS) with first-line pembrolizumab plus chemotherapy versus chemotherapy in advanced urothelial carcinoma. This prespecified exploratory analysis assessed the association of tumor mutational burden (TMB) and PD-L1 combined positive score (CPS) with clinical outcomes. Patients and Methods: TMB and PD-L1 CPS were determined via whole-exome sequencing and PD-L1 IHC 22C3 pharmDx, respectively. The association was evaluated in each treatment arm using logistic regression [objective response rate (ORR)] and Cox proportional hazards regression models (PFS and OS); one-sided (pembrolizumab monotherapy; pembrolizumab plus chemotherapy) and two-sided (chemotherapy) nominal P values were calculated. Significance was prespecified at α = 0.05 without multiplicity adjustment. Efficacy was evaluated by prespecified cutoffs of 175 mutations/exome (TMB) and CPS 10 (PD-L1). Results: Of the 993 treated patients, 820 (82.6%) and 993 (100%) had evaluable TMB and CPS data, respectively. Continuous TMB was positively associated with ORR, PFS, and OS for pembrolizumab monotherapy (one-sided P &amp;lt; 0.001, P &amp;lt; 0.001, and P = 0.007, respectively); PFS and OS for pembrolizumab plus chemotherapy (one-sided P = 0.007 and P = 0.010, respectively); and OS for chemotherapy alone (two-sided P = 0.040). Continuous PD-L1 CPS showed evidence of anticipated association with ORR and PFS for pembrolizumab monotherapy. The subgroup with TMB ≥175 mutations/exome and PD-L1 CPS ≥10 had the highest PFS and OS improvements with pembrolizumab alone or with chemotherapy versus chemotherapy alone. Conclusions: These data suggest that TMB may be predictive of the response to pembrolizumab alone or with chemotherapy in advanced urothelial carcinoma.
TAVR in Young Patients With Aortic Stenosis
Authors: Robert O. Bonow, Patrick T. O’Gara
Journal: JAMA Cardiology (2024)

Megan Coylewright, MD, MPH; Kendra J. Grubb, MD, MHA; Suzanne V. Arnold, MD, MHA; Wayne Batchelor, MD, MHS; Abhijeet Dhoble, MD, MPH; Aaron Horne Jr, MD, MBA, MHS; Martin B. Leon, MD; Vinod Thourani, MD; Tamim M. Nazif, MD; Brian R. Lindman, MD, MSc; Molly Szerlip, MD
Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era
Authors: Megan Coylewright, Kendra J. Grubb, Suzanne V. Arnold, Wayne Batchelor, Abhijeet Dhoble, Aaron Horne, Martin B. Leon, Vinod Thourani, Tamim M. Nazif, Brian R. Lindman, Molly Szerlip
Journal: JAMA Cardiology (2024)

Guidelines advise heart team assessment for all patients with aortic stenosis, with surgical aortic valve replacement recommended for patients younger than 65 years or with a life expectancy greater than 20 years. If bioprosthetic valves are selected, repeat procedures may be needed given limited durability of tissue valves; however, younger patients with aortic stenosis may have major comorbidities that can limit life expectancy, impacting decision-making.
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors
Authors: Clare E. Murray, Anand V. R. Kornepati, Carlos Ontiveros, Yiji Liao, Bárbara de la Peña Avalos, Cody M. Rogers, Zexuan Liu, Yilun Deng, Haiyan Bai, Suresh Kari, Alvaro S. Padron, Jacob T. Boyd, Ryan Reyes, Curtis A. Clark, Robert S. Svatek, Rong Li, Yanfen Hu, Meiling Wang, José R. Conejo-Garcia, Lauren A. Byers, Kavya Ramkumar, Anil K. Sood, Jung-Min Lee, Christin E. Burd, Ratna K. Vadlamudi, Harshita B. Gupta, Weixing Zhao, Eloïse Dray, Patrick Sung, Tyler J. Curiel
Journal: Molecular Cancer (2024)
Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period
Authors: Tammy L Kindel, Andrew Y Wang, Anupama Wadhwa, Allison R Schulman, Reem Z Sharaiha, Matthew Kroh, Omar M Ghanem, Shauna Levy, Girish P Joshi, Teresa L LaMasters
Journal: Clinical Gastroenterology and Hepatology (2024)
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer
Authors: Jing Yan, Di Chen, Zi Ye, Xuqiang Zhu, Xueyuan Li, Henan Jiao, Mengjiao Duan, Chaoli Zhang, Jingliang Cheng, Lixia Xu, Hongjiang Li, Dongming Yan
Journal: Molecular Cancer (2024)
EAACI guidelines on the management of IgE‐mediated food allergy
Authors: Alexandra F. Santos, Carmen Riggioni, Ioana Agache, Cezmi A. Akdis, Mubeccel Akdis, Alberto Alvarez‐Perea, Montserrat Alvaro‐Lozano, Barbara Ballmer‐Weber, Simona Barni, Kirsten Beyer, Carsten Bindslev‐Jensen, Helen A. Brough, Betul Buyuktiryaki, Derek Chu, Stefano Del Giacco, Audrey Dunn‐Galvin, Bernadette Eberlein, Motohiro Ebisawa, Philippe Eigenmann, Thomas Eiwegger, Mary Feeney, Montserrat Fernandez‐Rivas, Alessandro Fiocchi, Helen R. Fisher, David M. Fleischer, Mattia Giovannini, Claudia Gray, Karin Hoffmann‐Sommergruber, Susanne Halken, Jonathan O'B Hourihane, Christina J. Jones, Marek Jutel, Edward F. Knol, George N. Konstantinou, Gideon Lack, Susanne Lau, Andreina Marques Mejias, Mary Jane Marchisotto, Rosan Meyer, Charlotte G. Mortz, Beatriz Moya, Antonella Muraro, Caroline Nilsson, Lucila Camargo Lopes de Oliveira, Liam O'Mahony, Nikolaos G. Papadopoulos, Kirsten P. Perrett, Rachel Peters, Marcia Podesta, Lars K. Poulsen, Graham Roberts, Hugh Sampson, Jürgen Schwarze, Peter Smith, Elizabeth Tham, Eva Untersmayr, Ronald Van Ree, Carina Venter, Brian Vickery, Berber Vlieg‐Boerstra, Thomas Werfel, Margitta Worm, George Du Toit, Isabel Skypala
Journal: Allergy (2024)

This European Academy of Allergy and Clinical Immunology (EAACI) guideline provides recommendations for the management of IgE-mediated food allergy and was developed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Following the confirmation of IgE-mediated food allergy diagnosis, allergen avoidance and dietary advice (with support of a specialised dietitian, if possible) together with the provision of a written treatment plan, education on the recognition of allergic symptoms and prescription of medication including adrenaline using an auto-injector are essential. Patients with significant anxiety and requirement for coping strategies may benefit from support from a clinical psychologist. As immunomodulatory interventions, omalizumab is suggested for treatment of IgE-mediated food allergy in children from the age of 1 and adults; and oral allergen-specific immunotherapy is recommended for children and adolescents with peanut allergy and suggested for milk and egg allergies (generally after 4 years of age for milk and egg). Sublingual and epicutaneous immunotherapy are suggested for peanut allergy but are not yet available at the point of care. Future research into disease modifying treatments for IgE-mediated food allergy are highly needed, with standardised and patient-focused protocols and outcomes.
Sex dimorphism in kidney health and disease: mechanistic insights and clinical implication
Authors: Stefanie Steiger, Li Li, Annette Bruchfeld, Kate I Stevens, Sarah M Moran, Jürgen Floege, Fernando Caravaca-Fontán, Safak Mirioglu, Onno Y K Teng, Eleni Frangou, Andreas Kronbichler
Journal: Kidney International (2024)

Sex is a key variable in the regulation of human physiology and pathology. Many diseases disproportionately affect one sex: autoimmune diseases, such as systemic lupus erythematosus, are more common in women but more severe in men, whereas the incidence of other disorders such as gouty arthritis and malignant cancers is higher in men. Besides the pathophysiology, sex may also influence the efficacy of therapeutics; participants in clinical trials are still predominately men, and the side effects of drugs are more common in women than in men. Sex dimorphism is a prominent feature of kidney physiology and function, and consequently affects the predisposition to many adult kidney diseases. These differences subsequently influence the response to immune stimuli, hormones, and therapies. It is highly likely that these responses differ between the sexes. Therefore, it becomes imperative to consider sex differences in translational science from basic science to preclinical research to clinical research and trials. Under-representation of one sex in preclinical animal studies or clinical trials remains an issue and key reported outcomes of such studies ought to be presented separately. Without this, it remains difficult to tailor the management of kidney disease appropriately and effectively. In this review, we provide mechanistic insights into sex differences in rodents and humans, both in kidney health and disease, highlight the importance of considering sex differences in the design of any preclinical animal or clinical study, and propose guidance on how to optimal design and conduct preclinical animal studies in future research.
A Closed‐Loop Cascade Strategy for On‐Demand Regulation of Uric Acid
Authors: Chenyao Nie, Ji Xu, Yuhui Zhao, Ke Nan, Manqi Tan, Zhaobo Liu, Ming Huang, Wenzhi Ren, Bing Wang
Journal: Advanced Healthcare Materials (2024)

Abstract Despite that the current anti‐hyperuricemia drugs can effectively reduce uric acid (UA) levels, imprecise medication dosage or uncontrolled lowering of UA levels may result in undesired effects. To address this issue, a closed‐loop cascade strategy based on a biocompatible network composite, NW‐FPNP/uricase (UOX), is proposed for on‐demand regulation of UA levels. NW‐FPNP/UOX is constructed by encapsulation of UOX) as UA‐responsive element and FPNP, a nanoparticle of phenylboronic acid modified xanthine oxidase (XOD) inhibitor febuxostat, as H 2 O 2 ‐sensitive element with AMP/Gd 3+ network. It interrelates the UA metabolization and generation processes into a closed loop of cascade reactions involving UOX‐catalyzed UA metabolization and H 2 O 2 generation, H 2 O 2 ‐triggered febuxostat regeneration and XOD inhibition, and XOD‐catalyzed UA generation. Through UA level‐dependent auto‐adjustment of XOD activity, specially 6% at 600 × 10 −6 m UA compared to 82% at 100 × 10 −6 m , UA levels can be regulated to an appropriate range through dynamically balancing UA metabolization and generation. This biocompatible on‐demand UA regulation system prevents the overdose of UA‐lowering medications and avoids hypouricemia in hyperuricemia treatment, demonstrating great potential in intelligent UA level management. This work also introduces a new concept of a closed‐loop cascade strategy for on‐demand regulation of biochemical indicators within specific thresholds.
Renal colocalisation of Rosai-Dorfman-Destombes disease and secondary AA amyloidosis successfully treated with lenalidomide and dexamethasone
Authors: Rayane Benyahia, Charlotte Syrykh, Clotilde Gaible, Julie Belliere, Magali Colombat, Audrey Delas, Jérémie Dion, Pierre Cougoul
Journal: The Lancet Haematology (2024)
Exos‐Loaded Gox‐Modified Smart‐Response Self‐Healing Hydrogel Improves the Microenvironment and Promotes Wound Healing in Diabetic Wounds
Authors: Pu Yang, Yikun Ju, Naisi Shen, Shuai Zhu, Jiaqian He, Lingxiu Yang, Jiajie Lei, Xiaoli He, Wenjia Shao, Lanjie Lei, Bairong Fang
Journal: Advanced Healthcare Materials (2024)

Abstract Wound management has always been a challenge in the clinical treatment of diabetes. In this study, glucose oxidase (GOx) is grafted onto natural pullulan polysaccharides, and oxidization is carried out to form a self‐healing hydrogel using carboxymethyl chitosan by means of reversible Schiff base covalent bonding. The smart‐response drug release properties of this natural self‐healing hydrogel are demonstrated in diabetic wounds by taking advantage of two key factors, namely the pH‐responsive nature of Schiff base bonding and the fact that GOx reduces the pH in diabetic wounds. To further enhance the biological functions of the hydrogel dressing, exosomes (Exos) are introduced into the hydrogel system. The GOx present in the hydrogel system improves the high‐glucose microenvironment of diabetic wounds, releasing H 2 O 2 to impart antimicrobial effects, and ensuring that the hydrogel realizes a smart‐response function. The carboxymethyl chitosan component used to construct the hydrogel plays an effective antibacterial role. Moreover, the Exos loaded into the hydrogel effectively promotes neovascularization of the wound. The Exos also regulates macrophage polarization and reduces the levels of persistent inflammation in diabetic wounds. These results suggest that this smart responsive, multifunctional, and self‐healing hydrogel dressing is ideal for the management of diabetic wounds.
Mechanisms coupling lipid droplets to MASLD pathophysiology
Authors: Mari V. Reid, Gavin Fredickson, Douglas G. Mashek
Journal: Hepatology (2024)

Hepatic steatosis, the buildup of neutral lipids in lipid droplets (LDs), is commonly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) when alcohol or viral infections are not involved. MASLD encompasses simple steatosis and the more severe metabolic dysfunction-associated steatohepatitis (MASH), characterized by inflammation, hepatocyte injury, and fibrosis. Previously viewed as inert markers of disease, LDs are now understood to play active roles in disease etiology and have significant non-pathological and pathological functions in cell signaling and function. These dynamic properties of LDs are tightly regulated by hundreds of proteins that coat the LD surface, controlling lipid metabolism, trafficking, and signaling. The following review highlights various facets of LD biology with the primary goal of discussing key mechanisms through which LDs can promote the development of advanced liver diseases including MASH.
Multi‐Target Peptide Nanofiber Immunotherapy Diminishes Complement Anaphylatoxin Activity in Acute Inflammation
Authors: Helena Freire Haddad, Emily F. Roe, Vinicius Xie Fu, Elizabeth J. Curvino, Joel H. Collier
Journal: Advanced Healthcare Materials (2024)

Abstract The anaphylatoxins C3a and C5a are products of the complement cascade that play important and interrelated roles in health and disease. Both are potential targets for anti‐inflammatory active immunotherapies in which a patient's own immune system is stimulated to produce therapeutic immune responses against problematic self‐molecules. However, the complex and time‐dependent interrelations between the two molecules make dual targeting challenging. To investigate a dual‐target active immunotherapy against C3a and C5a and to systematically study the effect of varied degrees of responses against both targets, the study employed self‐assembled peptide immunogens capable of displaying a broad range of epitope compositions and Design‐of‐Experiments (DoE) approaches. Peptide nanofibers contained B‐cell epitopes of C3a and C5a in defined quantities, and intranasal immunization raised systemic and mucosal immunity against each target. In a lipopolysaccharide‐induced model of sepsis, increasing anti‐C5a responses are protective, whereas increasing anti‐C3a responses are detrimental, and survival rates are negatively correlated with anti‐C3a/anti‐C5a IgG titer ratio. This work highlights the interplay between the two molecules by making use of a modular, defined, and easily adjusted biomaterial‐based active immunotherapy platform.
Trends and inequalities in thinness and obesity among Chinese children and adolescents: evidence from seven national school surveys between 1985 and 2019
Authors: Xinli Song, Bin Zhou, Sarah Baird, Chunling Lu, Majid Ezzati, Li Chen, Jieyu Liu, Yi Zhang, Ruolin Wang, Qi Ma, Jianuo Jiang, Yang Qin, Ziqi Dong, Wen Yuan, Tongjun Guo, Zhiying Song, Yunfei Liu, Jiajia Dang, Peijin Hu, Yanhui Dong, Yi Song, Jun Ma, Susan M Sawyer
Journal: The Lancet Public Health (2024)
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the <scp>VICTOR</scp> trial
Authors: Yogesh N.V. Reddy, Javed Butler, Kevin J. Anstrom, Robert O. Blaustein, Marc P. Bonaca, Stefano Corda, Justin A. Ezekowitz, Carolyn S.P. Lam, Eldrin F. Lewis, JoAnn Lindenfeld, Ciaran J. McMullan, Robert J. Mentz, Christopher O'Connor, Mahesh Patel, Piotr Ponikowski, Giuseppe M.C. Rosano, Clara I. Saldarriaga, Michele Senni, James Udelson, Adriaan A. Voors, Faiez Zannad
Journal: European Journal of Heart Failure (2024)
What’s in a Name? Why Words Matter in Advanced Prostate Cancer
Authors: William K Oh, Neeraj Agarwal, Alan Bryce, Pedro Barata, Courtney Bugler, Sigrid V Carlsson, Brad Cornell, William Dahut, Daniel George, Stacy Loeb, Bruce Montgomery, David Morris, Lorelei A Mucci, Aurelius Omlin, Ganesh Palapattu, Irbaz Bin Riaz, Charles Ryan, Martin W Schoen, Samuel L Washington, Silke Gillessen
Journal: European Urology (2024)
Best Practice in Using Social Media: The European Association of Urology Position Statement
Authors: Jeremy Yuen-Chun Teoh, Nikita R Bhatt, Vito Cucchiara, Esther Garcia Rojo, Vineet Gauhar, Claudia Mercader, Benjamin Pradere, Wesley Verla, Julie Darraugh, Carla Bezuidenhout, Marc van Gurp, Elisabeth Hesston, Jarka Bloemberg, James N'Dow, Maria J Ribal, Gianluca Giannarini
Journal: European Urology (2024)
Molecular Engineering of Xanthene Dyes with 3D Multimodal‐Imaging Ability to Guide Photothermal Therapy
Authors: Li‐Na Zhang, Xiao‐Yun Ran, Hong Zhang, Yu Zhao, Qian Zhou, Shan‐Yong Chen, Cheng Yang, Xiao‐Qi Yu, Kun Li
Journal: Advanced Healthcare Materials (2024)

Abstract Phototheranostics integrates light‐based diagnostic techniques with therapeutic interventions, offering a non‐invasive, precise, and swift approach for both disease detection and treatment. The efficacy of this approach hinges on the multimodal imaging potential and photothermal conversion efficiency (PCE) of phototheranostic agents (PTAs). Despite the promise, crafting multifunctional phototheranostic organic small molecules brims with challenges. In this research, four innovative xanthene‐derived PTAs are synthesized by fine‐tuning the donor‐ π ‐acceptor (D‐ π ‐A) system to strike a balance between radiative and nonradiative decay. The inherent robust photostability and intense fluorescence of the traditional xanthene core are preserved, meanwhile the addition of highly electron‐withdrawing groups boosts the non‐radiative decay rate to enhance PCE and photoacoustic imaging capabilities. Remarkably, one of the PTAs, DMBA, demonstrates an exceptional absolute fluorescence quantum yield of 2.46% in PBS, and when encapsulated into nanoparticles, it achieves a high PCE of 79.5%. Consequently, DMBA nanoparticles (DMBA‐NPs) are effectively employed in fluorescence, 3D photoacoustic, and photothermal imaging‐guiding tumor photothermal therapy. This represents the first instance of a multimodal phototheranostic xanthene agent achieving synergistic fluorescence and photoacoustic imaging for diagnostic purposes. Furthermore, this work paves the way for leveraging xanthene fluorophores as versatile tools in the development of multifunctional reagents.
Ultraviolet radiation is not the major cause of melanoma mortality in the UK and sun exposure advice should be revised
Authors: Richard B Weller, Jiayue Gu
Journal: British Journal of Dermatology (2024)

Melanoma has the highest mortality of all skin cancers and efforts to reduce this are focussed on sun avoidance. Current UK guidance suggests that 86% of melanomas could be prevented by sun avoidance, which is considerably more than the 72% of lung cancers attributed to cigarette smoking. Unfortunately, the data on which the attributable risk of melanoma to sunlight are based are either speculative or incorrect and recent advances show that they and our approach to preventing melanoma deaths must be reconsidered.
Maximizing biological insights from instruments attached to animals
Authors: Roxanne S Beltran, A Marm Kilpatrick, Simona Picardi, Briana Abrahms, Gabriel M Barrile, William K Oestreich, Justine A Smith, Max F Czapanskiy, Arina B Favilla, Ryan R Reisinger, Jessica M Kendall-Bar, Allison R Payne, Matthew S Savoca, Danial G Palance, Samantha Andrzejaczek, Daphne M Shen, Taiki Adachi, Daniel P Costa, Natalie A Storm, Conner M Hale, Patrick W Robinson
Journal: Trends in Ecology & Evolution (2024)

Instruments attached to animals ('biologgers') have facilitated extensive discoveries about the patterns, causes, and consequences of animal behavior. Here, we present examples of how biologging can deepen our fundamental understanding of ecosystems and our applied understanding of global change impacts by enabling tests of ecological theory. Applying the iterative process of science to biologging has enabled a diverse set of insights, including social and experiential learning in long-distance migrants, state-dependent risk aversion in foraging predators, and resource abundance driving movement across taxa. Now, biologging is poised to tackle questions and refine ecological theories at increasing levels of complexity by integrating measurements from numerous individuals, merging datasets from multiple species and their environments, and spanning disciplines, including physiology, behavior and demography.
The 2024 report of the Lancet Countdown on health and climate change: facing record-breaking threats from delayed action
Authors: Marina Romanello, Maria Walawender, Shih-Che Hsu, Annalyse Moskeland, Yasna Palmeiro-Silva, Daniel Scamman, Zakari Ali, Nadia Ameli, Denitsa Angelova, Sonja Ayeb-Karlsson, Sara Basart, Jessica Beagley, Paul J Beggs, Luciana Blanco-Villafuerte, Wenjia Cai, Max Callaghan, Diarmid Campbell-Lendrum, Jonathan D Chambers, Victoria Chicmana-Zapata, Lingzhi Chu, Troy J Cross, Kim R van Daalen, Carole Dalin, Niheer Dasandi, Shouro Dasgupta, Michael Davies, Robert Dubrow, Matthew J Eckelman, James D Ford, Chris Freyberg, Olga Gasparyan, Georgiana Gordon-Strachan, Michael Grubb, Samuel H Gunther, Ian Hamilton, Yun Hang, Risto Hänninen, Stella Hartinger, Kehan He, Julian Heidecke, Jeremy J Hess, Louis Jamart, Slava Jankin, Harshavardhan Jatkar, Ollie Jay, Ilan Kelman, Harry Kennard, Gregor Kiesewetter, Patrick Kinney, Dominic Kniveton, Rostislav Kouznetsov, Pete Lampard, Jason K W Lee, Bruno Lemke, Bo Li, Yang Liu, Zhao Liu, Alba Llabrés-Brustenga, Melissa Lott, Rachel Lowe, Jaime Martinez-Urtaza, Mark Maslin, Lucy McAllister, Celia McMichael, Zhifu Mi, James Milner, Kelton Minor, Jan Minx, Nahid Mohajeri, Natalie C Momen, Maziar Moradi-Lakeh, Karyn Morrisey, Simon Munzert, Kris A Murray, Nick Obradovich, Megan B O'Hare, Camile Oliveira, Tadj Oreszczyn, Matthias Otto, Fereidoon Owfi, Olivia L Pearman, Frank Pega, Andrew J Perishing, Ana-Catarina Pinho-Gomes, Jamie Ponmattam, Mahnaz Rabbaniha, Jamie Rickman, Elizabeth Robinson, Joacim Rocklöv, David Rojas-Rueda, Renee N Salas, Jan C Semenza, Jodi D Sherman, Joy Shumake-Guillemot, Pratik Singh, Henrik Sjödin, Jessica Slater, Mikhail Sofiev, Cecilia Sorensen, Marco Springmann, Zélie Stalhandske, Jennifer D Stowell, Meisam Tabatabaei, Jonathon Taylor, Daniel Tong, Cathryn Tonne, Marina Treskova, Joaquin A Trinanes, Andreas Uppstu, Fabian Wagner, Laura Warnecke, Hannah Whitcombe, Peng Xian, Carol Zavaleta-Cortijo, Chi Zhang, Ran Zhang, Shihui Zhang, Ying Zhang, Qiao Zhu, Peng Gong, Hugh Montgomery, Anthony Costello
Journal: The Lancet (2024)